BioRestorative Therapies (FRA:9OF) Cyclically Adjusted FCF per Share: €-1,096.01 (As of Mar. 2026)


FRA:9OF BioRestorative Therapies Inc FRA:9OF
55 GF Score
Price €0.34
GF Value €1.40
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioRestorative Therapies Cyclically Adjusted FCF per Share?

BioRestorative Therapies FRA:9OF -0.59% 55 Cyclically Adjusted FCF per Share is €-1,096.01 as of Mar. 2026. GuruFocus rates FRA:9OF with a GF Score™ of 55/100 and a GF Value™ of €1.40 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BioRestorative Therapies's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.186. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-1,096.01 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 12.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of BioRestorative Therapies was 12.00% per year. The lowest was 7.80% per year. And the median was 8.20% per year.

As of today (2026-07-08), BioRestorative Therapies's current stock price is €0.336. BioRestorative Therapies's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-1,096.01. BioRestorative Therapies's Cyclically Adjusted Price-to-FCF of today is .


BioRestorative Therapies  (FRA:9OF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BioRestorative Therapies Cyclically Adjusted FCF per Share Related Terms


BioRestorative Therapies Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for BioRestorative Therapies's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioRestorative Therapies Cyclically Adjusted FCF per Share Chart

BioRestorative Therapies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,995.01 -2,035.31 -1,931.16 -1,857.81 -1,151.60

BioRestorative Therapies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,689.82 -1,438.27 -1,399.08 -1,151.60 -1,096.01

FRA:9OF vs CVKD, JSPR, APRE: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, BioRestorative Therapies's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioRestorative Therapies Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's Cyclically Adjusted Price-to-FCF falls into.


FRA:9OF
55GF Score
BioRestorative Therapies Inc FRA:9OF
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioRestorative Therapies Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioRestorative Therapies's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.186/330.2130*330.2130
=-0.186

Current CPI (Mar. 2026) = 330.2130.

BioRestorative Therapies Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -960.000 241.018 -1,315.273
201609 -1,103.000 241.428 -1,508.628
201612 -1,014.000 241.432 -1,386.875
201703 -1,140.000 243.801 -1,544.058
201706 -682.000 244.955 -919.374
201709 -427.000 246.819 -571.273
201712 -574.500 246.524 -769.529
201803 -469.500 249.554 -621.248
201806 -445.000 251.989 -583.140
201809 -580.000 252.439 -758.692
201812 -455.000 251.233 -598.038
201903 -438.000 254.202 -568.970
201906 -250.800 256.143 -323.325
201909 -259.000 256.759 -333.095
201912 -85.789 256.974 -110.239
202003 -1.018 258.115 -1.302
202006 -0.935 257.797 -1.198
202009 -1.113 260.280 -1.412
202012 -0.656 260.474 -0.832
202103 -0.861 264.877 -1.073
202106 -0.736 271.696 -0.895
202109 -0.614 274.310 -0.739
202112 -0.288 278.802 -0.341
202203 -0.439 287.504 -0.504
202206 -0.361 296.311 -0.402
202209 -0.396 296.808 -0.441
202212 -0.473 296.797 -0.526
202303 -0.613 301.836 -0.671
202306 -0.312 305.109 -0.338
202309 -0.091 307.789 -0.098
202312 -0.324 306.746 -0.349
202403 -0.320 312.332 -0.338
202406 -0.213 314.175 -0.224
202409 -0.189 315.301 -0.198
202412 -0.276 315.605 -0.289
202503 -0.312 319.799 -0.322
202506 -0.267 322.561 -0.273
202509 -0.271 324.800 -0.276
202512 -0.212 324.054 -0.216
202603 -0.186 330.213 -0.186

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-1,096.01 mean?
BioRestorative Therapies (FRA:9OF) has a Cyclically Adjusted FCF per Share of €-1,096.01 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BioRestorative Therapies and its competitors.
Is BioRestorative Therapies' Cyclically Adjusted FCF per Share too high?
BioRestorative Therapies' current Cyclically Adjusted FCF per Share is €-1,096.01. Overall, BioRestorative Therapies has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' Cyclically Adjusted FCF per Share compare to CVKD and JSPR?
BioRestorative Therapies' Cyclically Adjusted FCF per Share of €-1,096.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BioRestorative Therapies and its competitors. BioRestorative Therapies's current Cyclically Adjusted FCF per Share is €-1,096.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (FRA:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.40, compared to a current price of €0.34 — trading 76% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-1,096.01. BioRestorative Therapies' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For BioRestorative Therapies (FRA:9OF), the current Cyclically Adjusted FCF per Share is €-1,096.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioRestorative Therapies (FRA:9OF) Overvalued in 2026?

Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued. The current stock price of €0.34 is trading 76% below its estimated GF Value™ of €1.40. GuruFocus considers BioRestorative Therapies to be Possible Value Trap.

Key valuation signals for FRA:9OF:

  • Cyclically Adjusted FCF per Share: €-1,096.01
  • GF Value™: €1.40 vs. price of €0.34 (76% below fair value)
  • GF Score™: 55/100 with 3 warning signs

No single metric tells the full story. See the FRA:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioRestorative Therapies Business Description

Other Exchanges BRTX:USA
Address 40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
55GF Score

Get the complete analysis for FRA:9OF

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.34
Price
€1.40
GF Value